These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 23756202)

  • 1. Antibody conjugation via one and two C-terminal selenocysteines.
    Li X; Yang J; Rader C
    Methods; 2014 Jan; 65(1):133-8. PubMed ID: 23756202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecularly defined antibody conjugation through a selenocysteine interface.
    Hofer T; Skeffington LR; Chapman CM; Rader C
    Biochemistry; 2009 Dec; 48(50):12047-57. PubMed ID: 19894757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Utilization of Selenocysteine for Site-Specific Antibody Conjugation.
    Li X; Rader C
    Methods Mol Biol; 2017; 1575():145-164. PubMed ID: 28255878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stable and Potent Selenomab-Drug Conjugates.
    Li X; Nelson CG; Nair RR; Hazlehurst L; Moroni T; Martinez-Acedo P; Nanna AR; Hymel D; Burke TR; Rader C
    Cell Chem Biol; 2017 Apr; 24(4):433-442.e6. PubMed ID: 28330604
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of reagents for selenocysteine conjugation and the stability of selenocysteine adducts.
    Pedzisa L; Li X; Rader C; Roush WR
    Org Biomol Chem; 2016 Jun; 14(22):5141-7. PubMed ID: 27184239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Site-Specific Dual Antibody Conjugation via Engineered Cysteine and Selenocysteine Residues.
    Li X; Patterson JT; Sarkar M; Pedzisa L; Kodadek T; Roush WR; Rader C
    Bioconjug Chem; 2015 Nov; 26(11):2243-8. PubMed ID: 26161903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An engineered selenocysteine defines a unique class of antibody derivatives.
    Hofer T; Thomas JD; Burke TR; Rader C
    Proc Natl Acad Sci U S A; 2008 Aug; 105(34):12451-6. PubMed ID: 18719095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody-Drug Conjugates (ADCs) Derived from Interchain Cysteine Cross-Linking Demonstrate Improved Homogeneity and Other Pharmacological Properties over Conventional Heterogeneous ADCs.
    Behrens CR; Ha EH; Chinn LL; Bowers S; Probst G; Fitch-Bruhns M; Monteon J; Valdiosera A; Bermudez A; Liao-Chan S; Wong T; Melnick J; Theunissen JW; Flory MR; Houser D; Venstrom K; Levashova Z; Sauer P; Migone TS; van der Horst EH; Halcomb RL; Jackson DY
    Mol Pharm; 2015 Nov; 12(11):3986-98. PubMed ID: 26393951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Versatile Chemo-Enzymatic Conjugation Approach Yields Homogeneous and Highly Potent Antibody-Drug Conjugates.
    Xu Y; Jin S; Zhao W; Liu W; Ding D; Zhou J; Chen S
    Int J Mol Sci; 2017 Oct; 18(11):. PubMed ID: 29088062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetically Encoded Azide Containing Amino Acid in Mammalian Cells Enables Site-Specific Antibody-Drug Conjugates Using Click Cycloaddition Chemistry.
    VanBrunt MP; Shanebeck K; Caldwell Z; Johnson J; Thompson P; Martin T; Dong H; Li G; Xu H; D'Hooge F; Masterson L; Bariola P; Tiberghien A; Ezeadi E; Williams DG; Hartley JA; Howard PW; Grabstein KH; Bowen MA; Marelli M
    Bioconjug Chem; 2015 Nov; 26(11):2249-60. PubMed ID: 26332743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methods to Make Homogenous Antibody Drug Conjugates.
    Kline T; Steiner AR; Penta K; Sato AK; Hallam TJ; Yin G
    Pharm Res; 2015 Nov; 32(11):3480-93. PubMed ID: 25511917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methods to generate site-specific conjugates of antibody and protein.
    Park J; Lee S; Kim Y; Yoo TH
    Bioorg Med Chem; 2021 Jan; 30():115946. PubMed ID: 33360577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced tumor cell selectivity of adriamycin-monoclonal antibody conjugate via a poly(ethylene glycol)-based cleavable linker.
    Suzawa T; Nagamura S; Saito H; Ohta S; Hanai N; Kanazawa J; Okabe M; Yamasaki M
    J Control Release; 2002 Feb; 79(1-3):229-42. PubMed ID: 11853934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sortase Enzyme-Mediated Generation of Site-Specifically Conjugated Antibody Drug Conjugates with High In Vitro and In Vivo Potency.
    Beerli RR; Hell T; Merkel AS; Grawunder U
    PLoS One; 2015; 10(7):e0131177. PubMed ID: 26132162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment.
    McDonagh CF; Turcott E; Westendorf L; Webster JB; Alley SC; Kim K; Andreyka J; Stone I; Hamblett KJ; Francisco JA; Carter P
    Protein Eng Des Sel; 2006 Jul; 19(7):299-307. PubMed ID: 16644914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody drug conjugates.
    Bakhtiar R
    Biotechnol Lett; 2016 Oct; 38(10):1655-64. PubMed ID: 27334710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utilizing Solid-Phase to Enable High-Throughput, Site-Specific Conjugation and Dual-Labeled Antibody and Fab Conjugates.
    Puthenveetil S
    Methods Mol Biol; 2020; 2078():99-112. PubMed ID: 31643052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploiting the 21st amino acid-purifying and labeling proteins by selenolate targeting.
    Johansson L; Chen C; Thorell JO; Fredriksson A; Stone-Elander S; Gafvelin G; Arnér ES
    Nat Methods; 2004 Oct; 1(1):61-6. PubMed ID: 15782154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody-drug conjugates: recent advances in conjugation and linker chemistries.
    Tsuchikama K; An Z
    Protein Cell; 2018 Jan; 9(1):33-46. PubMed ID: 27743348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Engineered anti-CD70 antibody-drug conjugate with increased therapeutic index.
    McDonagh CF; Kim KM; Turcott E; Brown LL; Westendorf L; Feist T; Sussman D; Stone I; Anderson M; Miyamoto J; Lyon R; Alley SC; Gerber HP; Carter PJ
    Mol Cancer Ther; 2008 Sep; 7(9):2913-23. PubMed ID: 18790772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.